Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:CRBP NASDAQ:DWTX NASDAQ:KRRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.39-4.0%$2.73$0.97▼$3.60$179.85M0.32298,283 shs259,145 shsCRBPCorbus Pharmaceuticals$11.98-1.4%$9.85$6.72▼$20.56$225.11M2.68323,046 shs217,859 shsDWTXDogwood Therapeutics$1.98+6.5%$2.12$1.28▼$9.50$62.13M1.68125,816 shs83,549 shsKRROKorro Bio$11.08-1.1%$12.39$5.20▼$55.89$161.53M3.0788,759 shs63,132 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.02%-3.24%-10.82%-4.78%+143.88%CRBPCorbus Pharmaceuticals-1.40%+10.21%+19.56%+58.47%+70.17%DWTXDogwood Therapeutics+6.45%+26.92%+10.61%-35.50%-59.18%KRROKorro Bio-1.07%-14.04%-20.46%-0.81%-21.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.39-4.0%$2.73$0.97▼$3.60$179.85M0.32298,283 shs259,145 shsCRBPCorbus Pharmaceuticals$11.98-1.4%$9.85$6.72▼$20.56$225.11M2.68323,046 shs217,859 shsDWTXDogwood Therapeutics$1.98+6.5%$2.12$1.28▼$9.50$62.13M1.68125,816 shs83,549 shsKRROKorro Bio$11.08-1.1%$12.39$5.20▼$55.89$161.53M3.0788,759 shs63,132 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.02%-3.24%-10.82%-4.78%+143.88%CRBPCorbus Pharmaceuticals-1.40%+10.21%+19.56%+58.47%+70.17%DWTXDogwood Therapeutics+6.45%+26.92%+10.61%-35.50%-59.18%KRROKorro Bio-1.07%-14.04%-20.46%-0.81%-21.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67178.94% UpsideCRBPCorbus Pharmaceuticals 2.73Moderate Buy$42.33253.37% UpsideDWTXDogwood Therapeutics 2.00Hold$12.00506.06% UpsideKRROKorro Bio 2.70Moderate Buy$28.50157.22% UpsideCurrent Analyst Ratings BreakdownLatest DWTX, KRRO, CRBP, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.005/8/2026KRROKorro Bio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/27/2026DWTXDogwood Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026CRBPCorbus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026KRROKorro Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.21 per shareN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/A$6.82 per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A$2.33 per shareN/AKRROKorro Bio$6.39M25.00N/AN/A$8.29 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$2.01N/AN/AN/AN/A-123.07%-79.41%N/ACRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%N/ADWTXDogwood Therapeutics-$34.26M-$18.90N/AN/AN/AN/A-2,027.44%-31.29%N/AKRROKorro Bio-$117.26M-$11.67N/AN/AN/A-1,834.48%-117.86%-71.04%N/ALatest DWTX, KRRO, CRBP, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DWTXDogwood Therapeutics-$0.22-$0.15+$0.07-$0.15N/AN/A5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/7/2026Q1 2026KRROKorro Bio-$1.60-$1.69-$0.09-$1.69$0.76 millionN/A3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/AN/A3/18/2026Q4 2025DWTXDogwood Therapeutics-$1.22-$0.26+$0.96-$0.26N/AN/A3/12/2026Q4 2025KRROKorro Bio-$1.93-$5.32-$3.39-$5.32$0.43 million$1.29 million3/9/2026Q4 2025CRBPCorbus Pharmaceuticals-$1.78-$1.25+$0.53-$1.25$1.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.07CRBPCorbus PharmaceuticalsN/A7.928.07DWTXDogwood TherapeuticsN/A2.762.76KRROKorro BioN/A8.136.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CRBPCorbus Pharmaceuticals64.64%DWTXDogwood Therapeutics9.05%KRROKorro Bio13.18%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%CRBPCorbus Pharmaceuticals3.50%DWTXDogwood Therapeutics0.20%KRROKorro Bio4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million65.51 millionOptionableCRBPCorbus Pharmaceuticals4018.53 million17.12 millionOptionableDWTXDogwood Therapeutics533.40 million33.34 millionN/AKRROKorro Bio7014.42 million13.76 millionNo DataDWTX, KRRO, CRBP, and ABOS HeadlinesRecent News About These CompaniesAnalysts Have Conflicting Sentiments on These Healthcare Companies: CareCloud (CCLD) and Korro Bio (KRRO)May 10, 2026 | theglobeandmail.comKorro Bio (NASDAQ:KRRO) Announces Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comKorro Bio (NASDAQ:KRRO) Raised to "Sell" at Wall Street ZenMay 9, 2026 | marketbeat.comKorro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | globenewswire.comKorro to Participate in Upcoming Investor ConferencesMay 5, 2026 | globenewswire.comKorro Bio (KRRO) to Release Earnings on WednesdayMay 5, 2026 | americanbankingnews.comKorro Bio (KRRO) to Release Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comWhat Makes Korro Bio, Inc. (KRRO) a New Buy StockApril 28, 2026 | zacks.comKorro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 24, 2026 | marketbeat.comKorro Bio (NASDAQ:KRRO) Stock Price Down 0.8% - Should You Sell?April 21, 2026 | marketbeat.comKorro Announces Oral and Poster Presentations at Upcoming Scientific ConferencesApril 16, 2026 | globenewswire.comKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 10, 2026 | globenewswire.comTop 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2? (KRRO)April 6, 2026 | insidertrades.comKorro Bio Inc.April 2, 2026 | barrons.comRBC Capital Keeps Their Hold Rating on Korro Bio (KRRO)March 15, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)March 15, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Health Catalyst (HCAT)March 15, 2026 | theglobeandmail.comRaymond James upgrades Korro Bio (KRRO)March 14, 2026 | msn.comKorro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost OutlookMarch 13, 2026 | benzinga.comKorro Bio (NASDAQ:KRRO) Major Shareholder Anthony Jr. Florence Acquires 207,100 SharesMarch 13, 2026 | insidertrades.comNea 17 buys Korro Bio (KRRO) shares worth $2.3 millionMarch 13, 2026 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDWTX, KRRO, CRBP, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.39 -0.10 (-4.02%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.38 -0.01 (-0.21%) As of 05/14/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Corbus Pharmaceuticals NASDAQ:CRBP$11.98 -0.17 (-1.40%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$11.98 0.00 (0.00%) As of 05/14/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Dogwood Therapeutics NASDAQ:DWTX$1.98 +0.12 (+6.45%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.01 +0.03 (+1.46%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Korro Bio NASDAQ:KRRO$11.08 -0.12 (-1.07%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$11.04 -0.04 (-0.32%) As of 05/14/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
